

Attachment 6

Waiver of Human Subjects Committee



... Putting Technology To Work

**Centers for Public Health
Research and Evaluation**
100 Capitola Drive, Suite 301
Durham, North Carolina 27713-4411
Telephone (919) 544-3717
Fax (919) 544-0830

January 3, 2005


Ping Yu, PhD
Battelle/CPHRE
2101 Wilson Boulevard
Suite 800
Arlington, VA 22201-3008

Dear Dr. Yu:

As chair of the Battelle/CPHRE Institutional Review Board (IRB) I have reviewed the request for exemption dated 12/23/2004 for the study entitled "Drug-Free Communities Support Program National Evaluation" (FG467191-01) and grant an exemption for this study. This study is exempt per 45 CFR 46.101(b)(5).

Should any changes occur in your protocol that would change the scope of this project, please inform the IRB and submit a revised protocol for review. Similarly, the IRB needs to be notified in the event of any injury or unexpected outcome arising from this study.

Sincerely,


Margaret R. Pennybacker, PhD, CIP
IRB Chair

cc: Brigette Brevard
Lynda Huffines
Pamela Sutherland

Battelle/Centers for Public Health Research and Evaluation

100 Capitola Drive, Suite 301

Durham, NC 27713

Federal-wide Assurance No. FWA00004696

INSTITUTIONAL REVIEW BOARD NOTICE OF APPROVAL

PROJECT DIRECTOR: Ping Yu, PhD

PROJECT TITLE: Drug-Free Communities Support Program National Evaluation

CLIENT: Office of National Drug Control Policy

PROTOCOL DATE: 12/23/04

BATTELLE PROJECT CODE: FG467191-01

or PROPOSAL NUMBER: (if preaward)

NATURE OF REVIEW: (check one)

<input type="checkbox"/>
<input type="checkbox"/>
<input checked="" type="checkbox"/>

FULL MEETING DATE: _____

EXPEDITED (specify reason): _____ *Waiver*

EXEMPT (specify reason): Government program required by Congress; 45 CFR 46.101(b)(5)

TYPE OF APPROVAL: (check one)

<input type="checkbox"/>
<input type="checkbox"/>
<input type="checkbox"/>
<input type="checkbox"/>
<input type="checkbox"/>

PRELIMINARY. SCHEDULE NEXT REVIEW PRIOR TO INVOLVEMENT OF HUMAN SUBJECTS.

PRETEST/PILOT TEST. SCHEDULE NEXT REVIEW PRIOR TO FULL IMPLEMENTATION.

FULL IMPLEMENTATION.

RENEWAL.

AMENDMENT DATED

Please note the following requirements:

PROBLEMS OR ADVERSE REACTIONS: If any problems in treatment of human subjects or unexpected adverse reactions occur as a result of this study, you must notify the IRB Chairperson immediately, then complete an Adverse Event/Incident Report and forward it to the CPHRE IRB Administrator.

CHANGES IN PROTOCOL: If there are significant changes in procedures or study protocol, you must notify the IRB Chairperson and submit the revisions for review before they are implemented.

RENEWAL: You are required to apply for renewal of approval at least annually for as long as the study is active. Your next continuing review date should be on or before 11/3/05.

M R Pennybacker
IRB Chairperson

11/3/05
Date

Margaret R. Pennybacker, PhD, CIP
Print or Type Name

N/A Copy of approved Informed Consent on file.

cc: Project Director
IRB Administrator